We are live on ! Find out more
SRNE

Sorrento Therapeutics, Inc.

Delisted

SRNE was delisted on the 22nd of February, 2023.

84 hedge funds and large institutions have $114M invested in Sorrento Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 22 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more call options, than puts

Call options by funds: $870K | Put options by funds: $421K

36% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 22

5% less funds holding

Funds holding: 8884 (-4)

8% less capital invested

Capital invested by funds: $124M → $114M (-$9.94M)

22% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 18

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
84
Holders Change
-4
Holders Change %
-4.55%
% of All Funds
2.2%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
14
Increased
30
Reduced
22
Closed
18
Calls
$870K
Puts
$421K
Net Calls
+$449K
Net Calls Change
-$2.94M

SRNE Hedge Fund Activity: Q4 2015 in Review

84 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q4 2015, worth a combined $114M — down 8% from $124M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of SRNE and 14 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 30 added.

The largest buyer was Wildcat Capital Management, adding an estimated $7.7M. The largest seller was Avoro Capital Advisors, cutting an estimated $8.48M.

  • 84 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q4 2015, down from 88 in Q3 2015.
  • Funds reported $114M of Sorrento Therapeutics, Inc. stock for Q4 2015, down 8% quarter-over-quarter.
  • 14 funds opened new Sorrento Therapeutics, Inc. positions in Q4 2015 and 18 closed out, a net change of -4 holders.
  • The largest Sorrento Therapeutics, Inc. buyer in Q4 2015 was Wildcat Capital Management, an estimated $7.7M added.
  • The largest Sorrento Therapeutics, Inc. seller in Q4 2015 was Avoro Capital Advisors, an estimated $8.48M sold.

Based on aggregated 13F filings for Q4 2015.